Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Pharmacol Ther. 2020 Dec 1;221:107751. doi: 10.1016/j.pharmthera.2020.107751

Figure 1. Cancer therapy-induced senescence in cardiovascular cells.

Figure 1.

Cancer therapy induces senescence in different cardiovascular cells through a number of molecular mechanisms. Accumulation of senescent cells contributes to premature cardiovascular diseases in cancer survivors. Multiple interventions are proposed to mitigate cancer therapy-induced cardiovascular senescence. D+Q, Dasatinib and quercetin; IL-6, Interleukin-6; MMP, Matrix metalloproteinase inhibitor; NAC, N-acetyl cysteine; SA-β-gal, Senescence associated-β-galactosidase assay; SAHF, Senescence-associated heterochromatin foci; SASP, Senescence-associated secretory phenotype; TNF-α, Tumor Necrosis Factor-alpha.